Search results: (10000)
News Comparison of Pharmacological Properties of Micronized Diosmin and Hesperidin in the Treatment of Chronic Venous Insufficiency and Hemorrhoids
Diosmin and hesperidin belong to the group of bioflavonoids, which currently find wide application in the treatment of chronic venous insufficiency and hemorrhoidal disease. Both flavonoids have been described to have a similar, but still not fully understood mechanism of action. Nevertheless, diosmin significantly differs from hesperidin, especially in pharmacokinetic parameters, which makes it the main carrier of the effect of venotonics.
News Experiences with the Treatment of Coagulopathy in Obstetrics – ROTEM-Guided Algorithm
An observational study from a hospital in Liverpool, UK, was published in the journal Anaesthesia, where they implemented a bleeding management algorithm for obstetric procedures based on rotational thromboelastometry (ROTEM) testing. After 4 years of using this algorithm, it was found that selective administration of fibrinogen concentrates based on ROTEM results led to better clinical outcomes in the treatment of coagulopathy.
News Efficacy of Baricitinib in Long-term Therapy of Rheumatoid Arthritis
Baricitinib selectively and reversibly inhibits Janus kinases JAK1 and JAK2 and is used in the treatment of adults with active rheumatoid arthritis (RA). Its safety during long-term administration has already been demonstrated by previous analyses, with treatment durations of up to 7 years. Equally important is the long-term efficacy of this drug, which was the focus of work presented in June of this year at the annual European rheumatology congress EULAR 2020.
News Characteristics of Patients with Alpha-1 Antitrypsin Deficiency – Two-Year Data from the EARCO Registry
The international registry of individuals with alpha-1 antitrypsin deficiency (AATD) named EARCO has collected data on 1,044 patients from 15 countries, including the Czech Republic, over its first 2 years of existence. In December 2022, the characteristics of patients enrolled from February 2020 to May 2022 were published. They provide information on the prevalence of AATD genotypes, their clinical phenotypes, factors associated with worsening lung function, and the impact of augmentation therapy.
News Neutropenia with Thrombocytopenia after Alemtuzumab? − Case Report
Early neutropenia with thrombocytopenia is not a common side effect of alemtuzumab. However, the patient in the following case report by Italian colleagues was affected. What was the outcome?
News Lorlatinib showed significant benefit in 1st line treatment of advanced ALK-positive non-small cell lung carcinoma
In the international CROWN study, lorlatinib compared to crizotinib led to a 72% reduction in the risk of disease progression or death and significant improvement in intracranial response to treatment in previously untreated patients with advanced ALK-positive non-small cell lung carcinoma (NSCLC). The results were published in November 2020 in the prestigious New England Journal of Medicine.
News Criteria for Progression in Fibrotic Non-IPF Interstitial Lung Disease
Fibrotic interstitial lung disease (fILD) is a challenging condition to manage with limited therapeutic options and a poor prognosis. The currently published review analyzes the criteria for its progression defining the presence of progressive pulmonary fibrosis (PPF), describes their relative prevalence, and prognostic significance.
News The Future of Multiple Sclerosis – Time for a Change in Classification?
What are the latest findings on the etiopathogenesis of multiple sclerosis? Are they reflected in the current classification? And what will future therapy look like?
News Practical Experiences Using ZULP in Cardiology
The application of a product containing ferric carboxymaltose (FCM) or the use of a contrast agent with sulfur hexafluoride in microbubbles are examples of the use of specially accounted medicinal products (ZULP) in cardiology practice. "A benefit for the patient is that they receive the indicated preparation directly in the office and do not have to procure it themselves from a pharmacy," says Dr. Jiří Veselý, head physician of the Edumed cardiology clinic in Jaroměř, with whom we discussed the advantages and disadvantages of using ZULP and his experiences with this system.
News Efficacy and Safety of Gene Therapy Using Adeno-Associated Virus Vector in Patients with Choroideremia
Choroideremia (CHM) is a rare genetically conditioned retinal disease caused by mutations in the CHM gene, leading to a lack of production of the protein REP1 (ras-associated binding escort protein 1). Currently, there is no approved treatment for CHM. The aim of the study (Tübingen Choroideremia Gene Therapy) published last year in the journal JAMA Ophthalmology was to evaluate the safety and efficacy of subretinally applied gene therapy using an adeno-associated virus vector (AAV2), designed to deliver a functional copy of the CHM gene to patients with choroideremia.
News Detection of ceftazidime/avibactam-resistant Enterobacteriaceae strains using a new rapid test
Ceftazidime/avibactam (CZA) is a relatively new antibiotic with very good efficacy against carbapenem-resistant Enterobacteriaceae. Unfortunately, strains resistant to this antimicrobial treatment are now beginning to emerge. The authors of the presented study developed and tested a new laboratory test for the rapid and accurate detection of these multidrug-resistant Enterobacteriaceae.
News Current Treatment Options for Refractory/Relapsed CLL
How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A review published in Acta Haematologica discusses the current therapeutic options for relapsed or refractory disease.
News Prognostic Significance of Lymphopenia for Stratification of Patients with Follicular Lymphoma
The therapy of follicular lymphoma (FL) is guided by several prognostic indices, such as the Follicular Lymphoma International Prognostic Index (FLIPI). The retrospective analysis of 736 patients with FL presented below introduces a prognostic model combining FLIPI and absolute lymphopenia into an integrated FLIPI-L index. Absolute lymphopenia is crucial for stratifying patient OS and the risk of transformation.
News Summary Analysis of HAVEN 1–4 and Patient Case Studies from ÚHKT
MUDr. Věra Geierová from the Institute of Hematology and Blood Transfusion in Prague prepared a summary of what was discussed about emicizumab during the ASH 2020 congress for this year's Prague Hematology Days. In this context, she highlighted the comprehensive analysis of phase 3 HAVEN 1–4 studies, which assessed the safety and efficacy of emicizumab in individuals with hemophilia A with or without FVIII inhibitors.
News Cardiovascular System Affection in Children with Noonan Syndrome
Noonan syndrome is a genetically conditioned disease classified among the so-called RASopathies, caused by a germline mutation in the genes of the RAS/MAPK signaling pathway. Among other things, children with this disease typically present with cardiovascular system involvement.
News Educational Brochure for Patients with CLL
Thanks to the expansion of modern therapies for chronic lymphocytic leukemia, many patients now have regimens based on venetoclax. Do you want to help them better understand the practical aspects and principles of this therapy? For this purpose, the Czech Group for Chronic Lymphocytic Leukemia (ČSCLL) in collaboration with PharmDr. Petra Rozsívalová from the Department of Clinical Pharmacy of the Faculty of Medicine, Charles University, and the University Hospital Hradec Králové has compiled a new brochure. It clearly and simply informs how this treatment works, the available dosages, how to use it correctly, and the most common side effects. Of course, it includes many practical tips, such as what to do if a patient forgets to take a dose, which foods interact with the treatment, and whether it affects the efficacy of vaccinations.
News Parenteral Nutrition as Part of Cancer Patient Treatment
Malnutrition represents a potentially serious complication for cancer patients. If it is not possible to meet the nutritional demands of the body through the enteral route, parenteral nutrition must be initiated. A doctor will recommend it in situations where the patient is at risk from the consequences of malnutrition. Up to 45% of these patients struggle with at least a 10% loss of their body weight.
News OCA in Second-Line Treatment of PBC: Analysis Results and Real-World Data
Ursodeoxycholic acid (UDCA) is the cornerstone treatment for PBC according to the guidelines of the European Association for the Study of the Liver (EASL). However, many patients (25–50%) do not achieve an adequate response to it, and some patients develop intolerance leading to the necessity of discontinuation (in the phase III POISE study, this concerned 7% of participants). Then, obeticholic acid (OCA) is indicated, which is recommended as the only registered second-line treatment option for PBC by current professional guidelines both European (EASL 2017) and Czech (2018). The latest data on OCA from clinical studies as well as real-world practice was also presented at this year's XLVIII May Hepatology Days.
News Incidence of Osteoporosis in Patients with Atrial Fibrillation Treated with Different Oral Anticoagulants
Previous research has suggested an increased risk of osteoporosis and osteoporotic fractures in patients with atrial fibrillation treated with warfarin. A recent analysis also identified a higher incidence of osteoporosis in patients treated with warfarin or direct oral anticoagulants (DOACs). However, less is known about the risk of this disease when using DOACs compared to warfarin. Therefore, Australian doctors compared its incidence in patients treated with different oral anticoagulants for atrial fibrillation (AF) in a population cohort study using data from a nationwide primary care database.
News Etiology and Therapy of Dry Eye Syndrome in a Nutshell
Dry eye syndrome, the most common diagnosis in outpatient ophthalmology practice, is a multifactorial disease with varying severity of symptoms. It reduces the quality of life and can also affect the patient's visual functions. Therapy is individualized according to the primary trigger of the disease and aims to restore the homeostasis of the ocular surface and tear film. Due to the rapid pace of modernization associated with numerous extrinsic factors contributing to the development of dry eye syndrome, its incidence is rising, as well as the number of topical therapeutic options.
News Interaction of the 'Big Five' Helps Predict Depression
Experts refer to the 'Big Five' as a personality model that encompasses the following five dimensions: openness to experience, conscientiousness, extraversion, agreeableness, and neuroticism. Can this model be helpful in diagnosing depression?
News Bimekizumab in the treatment of moderate to severe hidradenitis suppurativa – another approved indication for this biological agent
In May, the primary results of the BE HEARD I and II studies evaluating the efficacy and safety of the IL-17A and IL-17F inhibitor bimekizumab in the treatment of moderate to severe hidradenitis suppurativa (HS) in adults were published in The Lancet. This is the first publication of the results of these Phase III studies. Based on these findings, the European Medicines Agency (EMA) approved bimekizumab (which is currently approved for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis) for the treatment of HS in adults who have not responded adequately to conventional systemic therapy.